Pennant Investors, LP Compass Therapeutics, Inc. Transaction History
Pennant Investors, LP
- $367 Million
- Q2 2024
A detailed history of Pennant Investors, LP transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Pennant Investors, LP holds 199,000 shares of CMPX stock, worth $340,290. This represents 0.05% of its overall portfolio holdings.
Number of Shares
199,000
Previous 199,000
-0.0%
Holding current value
$340,290
Previous $394,000
49.49%
% of portfolio
0.05%
Previous 0.1%
Shares
1 transactions
Others Institutions Holding CMPX
# of Institutions
82Shares Held
92.7MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA22.4MShares$38.2 Million0.54% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA11.1MShares$19 Million0.02% of portfolio
-
Blackstone Inc New York, NY7.69MShares$13.2 Million0.03% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$11.3 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD5.51MShares$9.43 Million0.17% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $173M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...